Market closed
MeiraGTx/$MGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Ticker
$MGTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
378
ISIN
KYG596651029
Website
MeiraGTx Metrics
BasicAdvanced
$431M
-
-$2.12
1.24
-
Price and volume
Market cap
$431M
Beta
1.24
52-week high
$8.75
52-week low
$3.85
Average daily volume
650K
Financial strength
Current ratio
2.032
Quick ratio
1.88
Long term debt to equity
119.044
Total debt to equity
125.02
Interest coverage (TTM)
-12.37%
Management effectiveness
Return on assets (TTM)
-34.41%
Return on equity (TTM)
-143.48%
Valuation
Price to revenue (TTM)
11.477
Price to book
6.32
Price to tangible book (TTM)
6.4
Price to free cash flow (TTM)
-3.49
Growth
Revenue change (TTM)
137.42%
Earnings per share change (TTM)
42.29%
3-year revenue growth (CAGR)
-4.07%
3-year earnings per share growth (CAGR)
5.50%
What the Analysts think about MeiraGTx
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
MeiraGTx Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MeiraGTx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MeiraGTx News
AllArticlesVideos
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease
GlobeNewsWire·1 day ago
Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more
GlobeNewsWire·2 weeks ago
MeiraGTx Holdings: Gaining Regulatory Focus
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MeiraGTx stock?
MeiraGTx (MGTX) has a market cap of $431M as of May 10, 2025.
What is the P/E ratio for MeiraGTx stock?
The price to earnings (P/E) ratio for MeiraGTx (MGTX) stock is 0 as of May 10, 2025.
Does MeiraGTx stock pay dividends?
No, MeiraGTx (MGTX) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next MeiraGTx dividend payment date?
MeiraGTx (MGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MeiraGTx?
MeiraGTx (MGTX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.